Table 1 Patient characteristics prior to CPDG2 administration

From: Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure

  Patient characteristics Study entry Prior CPDG 2 treatment Serum creatinine ( μ mol l−1)
Underlying disease Number of patients ( n) Sex (female/male) Age (years median range) MTX dose (g m−2) MTX infusion time (h) Intrathecal MTX therapy ( n) MTX serum level ( μ M ) (median (range)) Time from start of MTX infusion (h) (median (range)) MTX serum level ( μ M ) (median (range)) Time from start of MTX infusion (h) (median (range)) Prior to MTX infusion (median (range)) At study entry (median (range)) Prior to CPDG 2 treatment (median (range))
All patients 65 24/41 15.4 (0.9–71.8) 1–12 4–36 24 18 (0.52–1082) 47 (19–142) 11.93 (0.52–901) 52 (25–178) 61.1 (17.7–156.6) 185.6 (44.3–516.8) 177.9 (53.1–652.3)
ALL 26 8/18 14.1 (2.6–71.8) 1–8 6 (n=1), 24 (n=23), 36 (n=2) 18 18 (0.52–287) 48 (20–108) 10.66 (0.52–228) 52 (25–120) 45.1 (17.7–115.1) 99.12 (35.4–220.4) 136.3 (53.1–516.8)
NHL/Hodgkin's lymphoma 21/2 9/14 53.3 (4.3–68.9) 3–8 4–8 (n=10), 24 (n=13) 5 13.94 (1–420) 45 (26–142) 7.46 (0.8–260) 55 (34–178) 70.8 (35.4–144.3) 208.9 (44.3–513.3) 218.6 (44.3–513.3)
Osteosarcoma 12 4/8 15.3 (9.4–39.4) 12 4 (n=12)   248 (2.43–1082) 38.5 (19–70.5) 177 (2.43–901) 46 (25–78) 73.5 (35.4–156.6) 172.6 (88.5–516.8) 197.4 (88.5–652.3)
Brain tumour/pleural mesothelioma 3/1 3/1 12.2 (0.9–20.3) 3–5 4 (n=1), 24 (n=3) 1 3.6 (2.39–17.4) 58 (44.5–66) 2.45 (1.93–17.4) 64.5 (45–82) 63.7 (44.3–97.4) 105.3 (62–380.6) 127.4 (62–407.1)